5 trends tracked about this subject — the full history, oldest to newest below.
Novartis stock experiences a sharp decline following a Phase 3 failure for a dystrophy drug linked to its $12 billion Avidity acquisition.
Summit Therapeutics and Akeso report that their cancer drug ivonescimab has met overall survival goals in a Phase 3 lung cancer trial.
GSK advances its mRNA flu vaccine candidate to phase 3 trials following successful mid-stage performance data.
Eli Lilly is moving toward 2027 regulatory filings for retatrutide after successful Phase 3 obesity trials showing significant weight and A1C improvements.
Arrowhead stock surges to multi-year highs following a major Phase 3 trial success, while chief rival Ionis falls.